| Literature DB >> 34792543 |
Birgit S Blomjous1,2, Gayle R S Gajadin1, Alexandre E Voskuyl2, Louise Falzon3, Jan L Hoving4, Irene E M Bultink2, Marieke M Ter Wee1,2.
Abstract
OBJECTIVES: This systematic review assessed which variables are associated with or are predictors for work participation outcomes in patients with systematic lupus erythematosus (SLE).Entities:
Keywords: absenteeism; employment; prediction; presenteeism; systemic lupus erythematosus; work participation
Mesh:
Year: 2022 PMID: 34792543 PMCID: PMC9258549 DOI: 10.1093/rheumatology/keab855
Source DB: PubMed Journal: Rheumatology (Oxford) ISSN: 1462-0324 Impact factor: 7.046
Flowchart
Flowchart presenting the identification and screening of articles, the articles assessed for eligibility and the final included articles.
Overview of used outcome measures in association and prediction studies
| Presenteeism | Absenteeism | Employment status | |||
|---|---|---|---|---|---|
| Definition | Number of studies | Definition | Number of studies | Definition | Number of studies |
| Productivity loss | 2 [ | Sick leave days | 2 [ | Being employed | 3 [ |
| Mean h worked without impairment | 1 [ | Sick leave h | 2 [ | Working h per day/week | 2 [ |
| Work productivity impairment | 1 [ | Short-term disability h | 1 [ | Working 24 h per week or less | 1 [ |
| Unable to work more than two months since diagnosis | 1 [ | Working <9 months per year | 1 [ | ||
| Working 10+ h at baseline | 1 [ | ||||
| Newly employed | 1 [ | ||||
| Length of time until work entry | 1 [ | ||||
| Length of time until work loss | 3 [ | ||||
| Stop working | 1 [ | ||||
| Unemployment after three years | 1 [ | ||||
| Work disability | 4 [ | ||||
| Health-related job cessation | 1 [ | ||||
| Unpaid work | 1 [ | ||||
h: Hours.
Results of association studies reporting on demographic, disease and work-related variables associated with work participation in SLE
| Presenteeism* | Favorable work outcome** | Unfavorable work outcome*** | ||||||
|---|---|---|---|---|---|---|---|---|
| Independent variable | Result | OR [95% CI] | Independent variable | Result | OR [95% CI] | Independent variable | Result | OR [95% CI] |
| Demographic variables | ||||||||
| Younger age | Lower risk ( | Age (continuous): ß 0.97 [95%CI 0.96, 0.98] [ | Younger age | Lower risk ( |
Age 18–34 yrs Age (continuous): ß 1.06 [95%CI 1.02, 1.11] [ Age 18–34 yrs Age 18–34 yrs Age (continuous): ß 0.98 [95%CI 0.95, 1.00] [ | |||
| Caucasian ethnicity |
Lower risk ( | Non-Caucasian ethnicity | Caucasian ethnicity | Lower risk ( | African-Americans | |||
| Higher educational level | Lower risk ( | Completion of bachelor’s degree | Higher educational level |
Lower risk ( Lower risk ( |
High school education or less College graduate | |||
| Male gender | Lower risk ( | Female | ||||||
| Never married | Higher risk ( | Never married | ||||||
| Resident of North Carolina | Stable ( | North Carolina | ||||||
| Disease variables# | ||||||||
| Moderate disease activity score | Higher risk ( | Moderate (11–16) | Lower disease activity score | Lower risk ( |
SLAQ (continuous): ß 0.98 [95%CI 0.97, 0.99] [ Patient global assessment (continuous): ß 0.89 [95%CI 0.82, 0.98] [ | Higher disease activity score in the preceding two years | Higher risk ( | Mean SELENA-SLEDAI score in preceding 2 years (continuous): ß 1.20 [95%CI 1.02, 1.42] [ |
| Moderate fatigue score | Higher risk ( | Moderate | Diagnosed with cSLE | Higher risk ( | cSLE | Longer disease duration | Lower risk ( | Disease duration (continuous): ß 0.93 [95%CI 0.91, 0.94] [ |
| Severe fatigue score | Higher risk ( | Severe | Diagnosed with SLE compared with controls | Higher risk ( | SLE | Depression | Higher risk ( | CES-D (continuous): ß 1.03 [95%CI 1.01, 1.05] [ |
| Skin disease activity | Higher risk ( | Skin disease activity (y/n): | Dialysis | Higher risk ( | Dialysis | Thrombotic manifestations | Higher risk ( | Thrombotic manifestations (y/n): 3.2 [95%CI 1.7, 5.9] [ |
| Mild lung disease activity | Higher risk ( | Mild | Fewer lung manifestations in past 5 years | Lower risk ( | Lung manifestations in past 5 years (categorical): 0.45 [95%CI 0.20, 1.00] [ | Severe musculoskeletal manifestations | Higher risk ( | Severe musculoskeletal manifestations (y/n): 1.7 [95%CI 1.2, 2.5] [ |
| Moderate lung disease activity | Higher risk ( | Moderate | Arthritis | Higher risk ( | Arthritis (y/n): 3.3 [95%CI 1.2, 8.8] [ | |||
| Severe lung disease activity | Higher risk ( | Severe | Pleuritis | Higher risk ( | Pleuritis (y/n): 2.3 [1.1, 4.6] [ | |||
| Mild stroke syndrome | Higher risk ( | Mild | Higher fatigue | Higher risk ( |
FACIT-F (continuous): ß 1.06 [95%CI 1.01, 1.10] [ | |||
| Moderate stroke syndrome | Higher risk ( | Moderate | ||||||
| Severe stroke syndrome | Higher risk ( | Severe | ||||||
| Moderate cognitive disease activity | Higher risk ( | Moderate | ||||||
| Severe cognitive disease activity | Higher risk ( | Severe | ||||||
| Mild muscle disease activity | Higher risk ( | Mild | ||||||
| Moderate muscle disease activity | Higher risk ( | Moderate | ||||||
| Mild joint disease activity | Higher risk ( | Mild | ||||||
| Moderate joint disease activity | Higher risk ( | Moderate | ||||||
| Severe joint disease activity | Higher risk ( | Severe | ||||||
| Having SLE compared with controls | Higher risk ( |
SLE SLE | ||||||
| Work variables | ||||||||
| Higher level of physical functioning | Lower risk ( |
SF-36 physical functioning (continuous): 1.05 [1.03, 1.07] [ SF-36 physical functioning scale (continuous): ß 1.02 [95%CI 1.01, 1.03] [ | Higher level of physical functioning | Lower risk ( | SF-36 physical functioning scale (continuous): ß 0.99 [95%CI 0.98, 1.00] [ | |||
| Shorter time since last regular work | Lower risk ( | Years since regular work (continuous): ß 0.73 [95%CI 0.62, 0.85] [ | More physical job demands | Higher risk ( | Sum of physical job demands (continuous): ß 1.06 [95%CI 1.0, 1.1] [ | |||
| Being employed after three years compared with baseline | Lower risk ( | Being employed at follow-up compared with being employed at study entry: 2.25 [95%CI 1.4, 3.7] [ | Higher cognitive functioning | Lower risk ( | MOS cognitive functioning scale (continuous): ß 0.98 [95%CI 0.97, 0.99] | |||
| Currently employed at follow-up based on obesity status | Lower risk ( | Currently employed at follow-up based on obesity status at baseline for non-obese | Job tenure per 5 years | Lower risk ( | Job tenure per 5 years (continuous): ß 0.9 [95%CI 0.7, 0.97] [ | |||
| High job demands and low control | Higher risk ( | High job demands low control (y/n): 1.4 [95%CI 1.1, 1.7] [ | ||||||
The number of studies is indicated. All mentioned associations are statistically significant. In the case of multiple models per study, the outcome of the first model or most extensive model is shown. In the Online Supplementary Table 1, available at Rheumatology online, the other outcomes can be found. The studies of Drenkard, Garris and Narayanan et al. did not show ORs; therefore p-values are shown.
*Presenteeism work outcomes: work productivity impairment, work h missed due to SLE, work h missed for another reason.
**Favorable work outcomes: being employed, being continuously employed, length of time until work loss at first specific SLE manifestation, h worked, work entry among unemployed.
***Unfavorable work outcomes: loss of days from the workforce and non-workforce activity, length of time until work loss, health-related job cessation, work loss, work disability over ten years after diagnosis, work loss among employed at diagnosis, work loss among employed.
#Disease activity measured by Systemic Lupus Activity Questionnaire (SLAQ), patient global assessment and Safety of Estrogens in SLE National Assessment SLE Disease Activity Index (SELENA-SLEDAI).
aSLE: adulthood-onset SLE; CES-D: Center for Epidemiologic Studies Depression Scale; cSLE: childhood-onset SLE; FACIT-F: Functional Assessment of Chronic Illness Therapy Fatigue; MOS: Medical Outcomes Study; OR: odds ratio; SF36: Short Form 36; SLAQ: Systemic Lupus Activity Questionnaire.
Result of prediction studies reporting on demographic, disease and work-related variables predicting work participation in SLE
| Work outcomes* | Unfavorable work outcome | ||||
|---|---|---|---|---|---|
| Predictor | Result | Coefficient ( | Predictor | Result | OR [95% CI] |
| Demographic variables | |||||
| Younger age | Lower risk ( | Age (continuous): ß 1.1 [95% CI 1.02, 1.12] [ | |||
| Male gender | Higher risk ( | Male | |||
| Poverty | Higher risk ( | Poverty | |||
| Higher educational level | Lower risk ( |
Finished high school High school education or less Education (continuous): ß 0.09 [95%CI 0.01, 0.4] [ | |||
| Disease variables | |||||
| Higher pain score | Higher risk | Pain score (continuous): ß 0.16 (0.06) [ | Higher disease activity at diagnosis | Stable risk ( | First SLEDAI-2K score (continuous): ß 1.04 [95%CI 1.00, 1.08] [ |
| Higher disease activity during the study | Higher risk ( | SLAM-R average (continuous): ß 1.3 [95%CI 1.1, 1.4] [ | |||
| Longer total disease duration | Higher risk ( | Total disease duration (continuous): ß 1.2 [95%CI 1.1, 1.4] [ | |||
| Damage accrual | Higher risk ( | SDI at last visit (continuous): ß 1.4, [95%CI 1.1, 1.7] [ | |||
| Hypertension | Higher risk ( | Hypertension | |||
| Fibromyalgia | Higher risk ( | Fibromyalgia | |||
| Depression | Higher risk ( | BDI >10 (depression) | |||
| Pleuritis | Higher risk ( | Significant, data were not presented [ | |||
| Moderate or high aCL titers | Higher risk ( | Moderate or high aCL titers | |||
| Impairment in complex attention | Higher risk ( | Impairment in complex attention | |||
| Impairment in memory | Higher risk ( | Impairment in memory | |||
| Impairment in executive functions | Higher risk ( | Impairment in executive functions | |||
| Impairment in reasoning/problem solving | Higher risk ( | Impairment in reasoning/problem solving | |||
| Work variables | |||||
| Lower level of physical functioning | Higher risk | Level of physical functioning (continuous): ß 0.33 (0.09) [ | Higher physical demands of the job | Higher risk ( | Higher physical demands of the job (higher DOT level, continuous): ß 2.8 [95%CI 1.4, 5.4] [ |
| Lower level of psychological functioning | Higher risk | Level of psychological functioning (continuous): ß 0.18 (0.08) [ | |||
The number of studies is indicated. All mentioned predictors are statistically significant. Damage accrual by the Systemic Lupus International Collaborating Clinics Damage Index at the last visit. Depression measured by Beck Depression Inventory. Impairment in complex attention measured by Mini Mental State Examination. Impairment in memory measured by digit span forward, logical memory. Impairment in executive function measured by digit span backward, verbal phonemic fluency. Impairment in reasoning/problem solving measured by comprehension. Higher level of physical and psychological functioning measured by visual analogue scale (0–10).
*Work status outcomes are work disability [1–3], unemployment [4] and health-related job cessation [2]. Presenteeism outcome is productivity loss [23].
aCL: anticardiolipin antibodies; BDI: Beck Depression Inventory; DOT: Dictionary of Occupational Titles; OR: odds ratio; SDI: Systemic Lupus International Collaborating Clinics Damage Index; SLAM (-R): Systemic Lupus Activity Measure (- Revised); SLEDAI-2k: SLE Disease Activity Index 2000.
Results of risk of bias assessment using QUIPS
| Study participation | Study attrition | Prognostic factor measurement | Outcome measurement | Study confounding | Statistical analysis and reporting | |
|---|---|---|---|---|---|---|
| Al Dhanhani, 2009 | ± | – | – | ± | – | – |
| Appenzeller, 2009 | ± | ± | – | ± | – | – |
| Bertoli, 2006 | + | – | ± | + | NA | + |
| Campbell, 2009 | ± | – | ± | – | – | ± |
| Clarke, 1993 | ± | – | – | + | NA | ± |
| Drenkard, 2014 | + | – | ± | – | – | + |
| Garris, 2013 | – | – | – | + | – | ± |
| Katz, 2011 | – | – | – | + | – | ± |
| Lawson, 2014 | – | – | ± | + | – | + |
| Mok, 2008 | – | NA | + | – | – | – |
| Narayanan, 2013 | ± | NA | + | ± | – | – |
| Partridge, 1997 | – | – | + | + | NA | – |
| Yelin, 2007 | – | – | – | + | – | – |
| Yelin, 2009 | ± | – | + | + | – | – |
| Yelin, 2012 | – | – | + | + | + | + |
– = high risk of bias;
± = moderate risk of bias;
+ = low risk of bias.